1810020G14Rik Inhibitors
Chemical inhibitors of 1810020G14Rik function by disrupting various signaling pathways that are essential for its activity. Wortmannin and LY294002 are two compounds that target the phosphoinositide 3-kinase (PI3K) pathway, a critical signaling route for the regulation of cell growth and survival. By inhibiting PI3K, these chemicals directly decrease AKT phosphorylation, a process that is necessary for the activation of numerous proteins, including 1810020G14Rik. With the PI3K-AKT pathway inhibited, the phosphorylation and subsequent activation of 1810020G14Rik are decreased, leading to reduced function of the protein. Another compound, Rapamycin, acts further downstream by specifically inhibiting mammalian target of rapamycin (mTOR) complex 1 (mTORC1). This action results in a general decrease in protein synthesis and may affect the stability and activity of a range of proteins, including 1810020G14Rik.
Additionally, PD98059 and U0126 are inhibitors of the mitogen-activated protein kinase kinase (MEK), which is part of the MEK/ERK pathway. By preventing MEK from activating ERK, these inhibitors can reduce the phosphorylation of various proteins that rely on this signaling for their function. As a result, 1810020G14Rik, which may require ERK-mediated phosphorylation for its activity, has reduced function. Furthermore, SP600125 and SB203580 inhibit the JNK and p38 MAP kinase pathways, respectively. Inhibition of these kinases can prevent the activation of a subset of proteins, which includes 1810020G14Rik. Compounds like PP2 and AG490 target tyrosine kinases such as the Src family kinases and Janus kinase 2 (JAK2), respectively. By decreasing the phosphorylation of proteins involved in these signaling pathways, these inhibitors can also lead to a reduction in the activity of 1810020G14Rik. PD173074, a specific inhibitor of the fibroblast growth factor receptor (FGFR), disrupts FGFR signaling, which can affect the activity of proteins regulated by this pathway. Lastly, Bisindolylmaleimide I and Staurosporine are broad-spectrum kinase inhibitors, with the former targeting protein kinase C (PKC) and the latter being a potent inhibitor of a wide range of protein kinases. The inhibition of these kinases can lead to a decrease in the phosphorylation and activation of many proteins, which likely includes 1810020G14Rik, resulting in its decreased function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it can reduce the downstream AKT signaling which may be necessary for the activation or stabilization of 1810020G14Rik, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K, similar to Wortmannin. It blocks PI3K activity, potentially leading to decreased AKT phosphorylation and activity. Reduced AKT activity can diminish the phosphorylation of downstream targets, possibly including 1810020G14Rik, resulting in its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) complex 1 (mTORC1). Inhibition of mTORC1 can lead to a reduction in protein synthesis and cell growth, which may affect proteins such as 1810020G14Rik by reducing their functional activity or stability in the cell. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERK). By inhibiting MEK, PD98059 can prevent ERK activation, which may be necessary for the phosphorylation and function of 1810020G14Rik, thereby inhibiting its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also a MEK inhibitor that prevents the activation of ERK1/2. As with PD98059, by blocking the MEK/ERK pathway, U0126 can hinder the phosphorylation of substrates involved in cell cycle progression and survival, including potentially 1810020G14Rik, resulting in its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK activity can prevent the phosphorylation of JNK substrates that might be involved in the regulation or function of 1810020G14Rik, resulting in its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibiting p38 MAP kinase can disrupt the p38 MAPK signaling pathway, which is involved in stress responses and cytokine production. This disruption can lead to the inhibition of proteins regulated by this pathway, potentially including 1810020G14Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. By blocking Src kinase activity, PP2 can decrease the phosphorylation of Src substrates, which could be involved in the regulation or activity of 1810020G14Rik, leading to its inhibition. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $82.00 $323.00 $219.00 $85.00 | 35 | |
AG490 is a tyrosine kinase inhibitor that targets the Janus kinase 2 (JAK2). Inhibiting JAK2 can block JAK-STAT signaling pathways, which might be required for the function or regulation of proteins like 1810020G14Rik, resulting in its inhibition. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is an inhibitor of the fibroblast growth factor receptor (FGFR). By inhibiting FGFR, this chemical can hinder the FGFR signaling pathway, potentially affecting downstream proteins that are regulated by this pathway, which may include 1810020G14Rik, leading to its functional inhibition. | ||||||